Tag - BFRI

Biofrontera (NASDAQ:BFRI) announced completion of patient enrollment in the Phase 3 study of Ameluz topical gel for the treatment of Actinic Keratoses (AKs) on the extremities, neck, and trunk with photodynamic therapy...